Never heard of this one before. You have any general thoughts on them? I see market cap is only about $135M and they look like they have a bit of a pipeline, though I don't know if there's any quality in there (http://www.furiex.com/pipeline/ ). With respect to the Phase 2 IBD data you linked to, looks like primary endpoint pertained to composite of stool consistency and abdominal pain at week 4 compared to baseline and their drug showed about 14% response at highest dose rate compared to just about 6% for placebo, which was stat sig. It's curious that the lowest dose was also stat sig, but the middle dose was not. Anyways, do you think the 14% versus 6% is real impressive or is this one of those cases where we should not just look at percentage improvement relative to placebo, but the overall impact? I.e., is 14% response really a dramatic clinical benefit for this drug?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.